Transcatheter Technologies expands platform with transfemoral system to complement its ‘truly repositionable’ Trinity TAVI system

REGENSBURG, Germany, Transcatheter Technologies GmbH, an emerging medical device company that has developed a third-generation transapical transcatheter aortic valve implantation (TAVI) system—Trinity—announced today that it has expanded the Trinity technology platform to include a transfemoral version as well.

In September of this year, Transcatheter Technologies disclosed at the ‘TCT 2014’ scientific meeting the successful one-year follow-up results of its “truly repositionable” Trinity transapical TAVI system, designed to be the world’s best TAVI system. Unlike currently marketed TAVI systems, the Trinity aortic valve can be positioned precisely or even repositioned after full implantation in a safe manner. Equally important, Trinity’s unique sealing cuff continues to provide outstanding results without PVL, a well-known and frequent complication of TAVI. Furthermore, the risk of atrio-ventricular (AV) block has been essentially alleviated because of the supra-annular anchoring of the Trinity valve.

 “We will expand our platform technology with a transfemoral system to complete our truly repositionable Trinity TAVI system. The transfemoral Trinity system will have the same features as our transapical system,” said Wolfgang Goetz, M.D., Ph.D., CEO, a cardiac surgeon who has used many of the currently marketed TAVI systems. “The tremendous advantage of Trinity is that even when the valve is completely expanded and anchored above the annulus—unlike currently marketed TAVI systems—the Trinity valve may still be repositioned, retrieved, or kept in the same position. This feature is absolutely unique to Trinity and the reason why we have positioned Trinity as the Third-Generation TAVI System.”